News
Intensified therapy can delay anti-TNF use for active RA
Major finding: At 12 months, HAQ scores were lower in patients treated with DMARDs than in patients treated with a TNF inhibitor (1.35 vs. 1.60; P...
News
ERCC1 fails to predict chemo response in NSCLC
Major finding: The hazard ratio for death in patients with ERCC1-negative tumors was 1.16 (P = .62), and for ERCC1-positive tumors it was 0.78 (P...
News
Prolonged antibiotic use reduced bronchiectasis exacerbations
Major finding: Pulmonary exacerbations occurred less frequently with erythromycin (1.29 vs. 1.97/patient per year, P = .003) or azithromycin (...
News
Gene alteration lowers bladder cancer risk
Major finding: A 0.77-fold reduced risk of bladder cancer was associated with a single nucleotide polymorphism (rs10759) found on the RGS4 gene....
News
In Europe, melanoma is rising in men over 60
Major Finding: In 1971, 32% of 1,094 malignant melanomas registered in England occurred in men; in 2009, 48% of 9,771 registrations were in men....
News
Geriatric Assessment Predicts Falls, Functioning in Elderly Cancer Patients
Major Finding: ADL worsened in 17.2% of elderly cancer patients, and IADL in 38.9%, and 17.5% experienced at least one fall.Data Source: Data are...
News
Age Ups Risk of Other Cancers in Breast Cancer Survivors
Major Finding: Crude 10-year incidences of multiple primary malignancy were 11.7, 16.7, 17.8, and 16.4/10,000 person-years for women younger than...
News
Triple-Negative Breast Cancer Shows Less Aggressive Biology in Elderly
Major Finding: Older women were less likely to have tumors that were positive for Ki67 (48% vs. 87.7%) or p53 (44.6% vs.
News
Cetuximab Fails First-Line in Gastric Cancer
Major Findings: Median progression-free survival was 4.4 vs.
News
Can Lapatinib Prevent Brain Metastases from Breast Cancer? Data 'Inconclusive'
Major Findings: The primary end point of CNS as first site of relapse was no different comparing lapatinib-capecitabine (3%) vs. trastuzumab-...
News
TURANDOT Revisits Bevacizumab Partners in Metastatic Breast Cancer
Major Finding: Secondary end points of progression-free survival (HR 1.36, P = .005) and objective response rates (P less than .0001) were...
News
Baseline Factors Trump Response to Therapy in Mastectomy Decisions
Major Findings: Half of all patients treated with a dual HER2 blockade and paclitaxel achieved a pathological complete response, but 58.6% went on...
News
Cetuximab Fails First-Line in Gastric Cancer
Major Findings: Median progression-free survival was 4.4 vs.
News
Lenalidomide Worsens Survival in Advanced Prostate Cancer
Major Finding: Median overall survival was 19.5 months in patient given lenalidomide plus docetaxel and prednisone but was not reached in the...